Tone Deafness Explained
- Date:
- August 26, 2007
- Source:
- Harvard Medical School
- Summary:
- Do people cringe when you sing? You've got company. But researchers have found that only 1 in 20 people truly has amusia, the technical term for tone deafness. Tests have shown that some people with bad singing voices hear music just fine. Amusics are a smaller group with a perceptual problem: They can't pick out differences in pitch or follow the simplest tunes.
- Share:
Do people cringe when you sing? You’ve got company. But researchers have found that only 1 in 20 people truly has amusia, the technical term for tone deafness. Tests have shown that some people with bad singing voices hear music just fine. Amusics are a smaller group with a perceptual problem: They can’t pick out differences in pitch or follow the simplest tunes, reports the September 2007 issue of the Harvard Health Letter.
Brain scans haven’t revealed major anatomical differences in amusics, but more sophisticated tests have uncovered some subtle variations. In a study comparing amusics to people with normal musical ability, researchers used a brain imaging and statistical technique to measure the density of the white matter (which consists of connecting nerve fibers) between the right frontal lobe, where higher thinking occurs, and the right temporal lobes, where basic processing of sound occurs. The white matter of the amusics was thinner, which suggests a weaker connection. Moreover, the worse the tone deafness, the thinner the white matter.
Some experts believe there’s a great deal of overlap between how the brain handles music and how it handles speech, which also has elements of pitch and rhythm. Others, though, believe that musical perception and thinking occur separately from other functions, and that our brains are predisposed toward developing centers and networks dedicated exclusively to music.
If you want to test your ability to perceive music, the Harvard Health Letter refers readers to an online test at http://www.delosis.com/listening developed by researchers at the University of Newcastle-upon-Tyne in England.
Story Source:
Materials provided by Harvard Medical School. Note: Content may be edited for style and length.
Cite This Page: